MPO and stroke disorder: It has been noted that 14-day BCA supplementation, at a dose of 10–40 mg/kg, resulted in a dose-depended reduction in the volume of stroke and cerebral edema in rats, with a simultaneous reduction in the parameters of neuroinflammation (levels of IL-1β and TNF-α) and myeloperoxidase (MPO) activity by inhibiting the p38 pathway [77].